RxDoctor Payments Data

Tiffany Abode

Family · Manalapan, NJNPI 1184234445

Payments from drug & device makers

$1,953in general payments, 2019–2025

Across 50 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$470
  • Boston Scientific$198
  • Edwards Lifesciences$190
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$187
  • Alnylam Pharmaceuticals Inc.$125
  • Kestra Medical Technology Services, Inc.$101
  • plus $682 from 21 others

What the payments were for

  • Travel & lodging$47024%
  • Food & beverage$1,48376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,953 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$314
Medicare patients
11
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban26$40,654
EliquisApixaban32$36,400
Rosuvastatin Calcium81$1,068
Olmesartan Medoxomil13$856
Metoprolol Succinate47$705
Ezetimibe26$465
Atorvastatin Calcium48$427
ClopidogrelClopidogrel Bisulfate26$408
Valsartan22$337
Amlodipine Besylate42$285
Losartan Potassium31$284
Hydralazine Hcl11$198
Carvedilol30$180
Metoprolol Tartrate12$83
Furosemide15$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$62$40,65426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.

Other family in Manalapan

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →